查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1372931

抗真菌藥物市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、適應症、感染類型、給藥途徑、最終用戶、配銷通路、地區和競賽

Anti-Fungal Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2018-2028 Segmented By Drug Class, By Indication, By Infection Type, By Route of Administration, By End User, By Distribution Channel, By Region & Competition
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球抗真菌藥物市場價值為 138.9 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年年複合成長率為 4.59%。抗真菌藥物通常用於治療真菌感染。這些藥物可以口服、局部或經由靜脈注射靜脈注射。酵母菌感染、癬、指甲和皮膚病等真菌感染可能是由土壤、空氣和皮膚中存在的真菌引起的。吸入真菌孢子也可能導致呼吸系統問題。因此，免疫系統較弱的人更容易受到真菌感染，因此需要使用抗真菌藥物。大多數這些藥物需要醫生處方，但也有一些可以在櫃檯購買。

主要市場促進因素

市場概況
預測期 2024-2028
2022 年市場規模 138.9億美元
2028 年市場規模 181.6億美元
2023-2028 年年複合成長率 4.59%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

真菌感染盛行率上升

真菌感染的日益普及是市場收入成長的關鍵驅動力。研究表明，真菌病原體每年導致全世界約 1300 萬人感染和 150 萬人死亡。抗真菌藥物也可口服。 2023 年3 月30 日，GSK plc 和SCYNEXIS, Inc. 宣布簽署Brexafemme 的獨家許可協議，Brexafemme 是美國食品和藥物管理局(FDA) 批准用於治療外陰陰道念珠菌病(​​VVC) 的一流抗真菌藥物.降低復發性 VVC (RVVC) 的發生率。這項獨家許可協議授予葛蘭素史克將Brexafemme 用於VVC 和RVVC 的商業化的獨家權利，同時繼續開發ibrexafungerp，該藥物目前正在進行III 期臨床試驗，用於可能治療侵襲性念珠菌病(​​IC )，這是一種可能致命的真菌感染。

近年來，真菌感染的盛行率不斷上升，引起了醫療保健行業的擔憂。造成這一令人震驚的趨勢的因素包括全球氣溫升高、慢性疾病的流行和免疫系統受損。根據美國疾病管制與預防中心 (CDC) 的數據，醫院獲得性真菌感染或院內感染已成為一個重大問題，2019 年約有 170 萬名住院患者感染此類感染。

為此，全球抗真菌藥物市場正在經歷顯著成長，市場參與者正在開發唑類等先進治療方法來有效對抗這些感染。

住院人數增加

住院人數的增加是導致醫療機構內真菌感染發生率不斷上升的關鍵因素。這種情況在患有癌症等慢性疾病的人和接受造血幹細胞移植的人中尤其普遍，他們的免疫系統較弱，需要經常去醫院就診和延長住院時間。由於這些患者通常需要密集的醫療干涉和長時間的住院治療，因此他們更容易受到在醫療環境中繁殖的機會性真菌病原體的影響。

值得注意的是，這些風險在醫療基礎設施不足的中低收入經濟體中更為明顯。在這些環境中，有限的資源和過度擁擠可能會進一步增加劇院內感染的傳播，對患者的健康構成重大威脅。這些地區缺乏適當的感染控制措施和有效的抗真菌治療方案，進一步加劇了醫療保健提供者面臨的挑戰。

鑑於這些具有挑戰性的條件，全球抗真菌藥物市場預計將蓬勃發展，因為它努力解決和應對這些複雜的醫療保健挑戰。創新抗真菌療法的開發和綜合感染控制方案的實施對於減輕真菌感染負擔和改善全球患者的治療效果至關重要。

增加醫療基礎建設投資

影響抗真菌藥物市場成長率的另一個重要因素是醫療保健支出的增加，這不僅有助於改善基礎設施，而且有助於先進治療方案的開發。隨著資金的增加，醫療機構可以提升其能力並投資於研發，以發現更有效的抗真菌藥物。

此外，公共和私人組織都在採取越來越多的措施來提高人們對多種真菌感染的盛行率和嚴重程度的認知。這些意識計劃旨在教育公眾和醫療保健專業人員了解早期診斷和適當治療的重要性。這種增強對真菌感染知識和理解的共同努力預計將推動抗真菌藥物的需求並擴大市場。

此外，由於高可支配收入和抗真菌藥物作為非處方藥（OTC）的供應不斷增加等因素，預計該市場將出現成長。非處方抗真菌藥物的易獲取性和便利性可能有助於其廣泛使用並推動市場擴張。

此外，全球老年人口不斷增加，導致包括真菌感染在內的各種疾病的盛行率增加。因此，發展中地區對抗真菌藥物的需求不斷成長，以滿足老齡化人口的醫療保健需求。這種人口結構的變化，加上針對各種醫療狀況的抗真菌藥物消費量的增加，預計將進一步提高抗真菌藥物市場的成長率。不斷成長的醫療保健支出、意識舉措、非處方藥的可用性以及老年人口不斷成長的需求，共同推動了抗真菌藥物市場的成長。

非處方 (OTC) 抗真菌藥物數量不斷增加

作為非處方藥 (OTC) 的抗真菌藥物的供應不斷增加，確實導致了對這些藥物的需求不斷成長。抗真菌藥物對於治療多種真菌感染至關重要，包括腳氣、酵母菌感染和癬。非處方抗真菌藥物在藥局、藥局甚至網路市場都很容易買到。患者無需處方即可購買它們，使尋求緩解常見真菌感染的個人更容易獲得它們。非處方藥的可用性使個人能夠自我診斷和自我治療常見的真菌感染。他們不再需要為每次輕微感染就去看醫療保健專業人員，這不僅節省了時間，還減輕了醫療保健系統的負擔。隨著非處方抗真菌藥物變得越來越普遍，消費者越來越意識到它們的可用性和功效。這種意識推動了需求，因為當人們知道可以輕鬆獲得有效的補救措施時，他們更有可能尋求治療。非處方抗真菌藥物為消費者提供隱私和便利。許多人喜歡謹慎地處理真菌感染，而不與醫療保健提供者討論他們的病情。這種對隱私的偏好鼓勵個人獨立購買這些藥物。

作為非處方藥的抗真菌藥物的數量不斷增加，從而擴大了它們的需求。這一轉變使消費者能夠掌控自己的健康並獨立治療常見的真菌感染，從而有助於抗真菌藥物在治療一系列真菌相關疾病方面的整體可及性和實用性。

主要市場挑戰

對健康的不利影響

抗真菌藥物有幾個缺點。一個關鍵因素是，免疫系統較弱的個體，例如患有後天免疫缺乏症候群（愛滋病）、狼瘡、癌症和其他疾病的個體，更容易受到危險的真菌感染（稱為機會性感染）的影響。這一漏洞對抗真菌藥物市場的收入成長構成了挑戰。

此外，藥物的類型、劑量強度和所治療的特定真菌都會影響藥物的效果。常見的副作用可能包括腹部疼痛、胃部不適、腹瀉、皮膚搔癢、灼熱或出疹。這些症狀也會對市場的收入成長產生負面影響。

除了這些挑戰之外，抗黴菌藥物還會產生重大副作用，包括黃疸、過敏反應和其他嚴重過敏反應等肝損傷。水泡和皮膚脫皮也是使用抗真菌藥物可能導致的嚴重過敏性皮膚反應的症狀。考慮到這些因素，很明顯，雖然抗真菌藥物對於治療真菌感染是必要的，但它們確實具有需要考慮的重大缺點。

抗真菌藥物抗藥性增加

對抗真菌藥物的抗藥性不斷增加是一個令人擔憂的趨勢，有可能減少對這些藥物的需求。當真菌發展出抵抗抗真菌藥物作用的機制，使其效果降低或無效時，就會出現抗真菌抗藥性。抗真菌抗藥性會使真菌感染的治療變得複雜。當抗真菌藥物療效降低時，患者可能需要更高劑量、延長療程或更有效的藥物。這可能會導致醫療費用增加和潛在的副作用，使個人不太願意尋求治療。隨著抗藥性的出現，可能會限制可用的有效抗真菌藥物的數量。在嚴重或抗藥性真菌感染的情況下，治療選擇的減少可能特別成問題，可能會減少對抗真菌藥物的需求。對替代抗真菌藥物或聯合療法來對抗抗藥性感染的需求可能會導致更高的醫療支出。患者和醫療保健提供者可能對投資昂貴的治療猶豫不決，從而影響了對這些藥物的整體需求。抗真菌抗藥性是一個公共衛生問題，因為它可能導致治療失敗、死亡率增加以及抗藥性真菌菌株的傳播。這種擔憂可能促使醫療保健系統和組織實施更嚴格的控制措施，包括限制抗真菌藥物的使用，這可能會影響需求。

主要市場趨勢

研發活動數量的增加

抗真菌藥物領域研發（R＆D）活動數量的增加預計將顯著增加對這些藥物的需求。抗真菌藥物對於治療各種真菌感染至關重要，從腳氣等表淺疾病到危及生命的全身性感染。不斷增加的研發投資導致新的抗真菌化合物和製劑的發現。這些創新可能會導致開發出更有效的藥物，並改善作用機制，從而增加可用的治療選擇。研發工作致力於了解和對抗抗真菌抗藥性。研究人員正在努力確定抗藥性背後的機制，並制定克服抗藥性的策略。這將確保抗真菌藥物的持續有效性，從而推動其需求。真菌生物學領域的研究正在揭示真菌細胞內可用於藥物開發的特定分子標靶。標靶治療可以增強藥物療效並減少副作用，使抗真菌藥物對醫療保健提供者和患者更具吸引力。

診斷測試和設備的技術進步

診斷測試和設備的技術進步預計將在增加抗真菌藥物的需求方面發揮至關重要的作用。技術進步使得能夠更早、更準確地識別真菌感染。快速診斷測試可以快速確認真菌的存在，使醫療保健提供者能夠及時開始治療。這種早期干涉對於防止真菌感染的進展至關重要，從而增加了抗真菌藥物的需求。先進的診斷方法可以區分各種真菌種類，有助於客製化治療方法。一些抗真菌藥物對特定真菌更有效，準確的物種鑑定可確保選擇最合適的藥物，從而可能推動對靶向抗真菌藥物的需求。

現代診斷設備可以評估真菌分離株對不同抗真菌藥物的敏感性。這些資訊指導臨床醫生選擇最有效的治療方法，減少抗藥性產生的可能性並促進對特定抗真菌藥物的需求。

細分市場洞察

藥品類別見解

2022年，包括Noxafil、Diflucan、Vfend和Cresemba等熱門治療藥物在內的唑類藥物類別將成為抗真菌藥物的領先細分市場。這種優勢可歸因於唑類表現出的廣譜活性。透過抑制真菌酶，這些物質有助於抑制真菌作用。唑類藥物用於治療眼部真菌感染、系統性念珠菌症、芽生菌病和念珠菌血症。三唑和咪唑是兩種唑類藥物，由於其廣泛的活性和良好的安全性，也可用於治療系統性真菌感染。三唑類藥物具有優異的吸收和分佈特性、較少的副作用以及最小的藥物交互作用風險。

抗真菌藥物市場預計將緩慢成長，這主要是由於念珠菌和曲霉菌的抗藥性不斷升級，特別是對唑類藥物的抗藥性。相反，稱為烯丙胺的合成殺菌化合物預計在整個預測期內將呈現穩定的年複合成長率(CAGR)。這些藥物被推薦用於治療癬、腳氣、股癬和指甲感染。繼氟康唑之後，蘭美抒是皮膚科醫師最常推薦用於全身性抗黴菌治療的外用抗黴菌藥物。因此，預計皮膚病患病率的增加將進一步促進該細分市場的成長。

適應症見解

最常見的系統性真菌感染念珠菌病預計在預測期內具有最高的年複合成長率(CAGR)。它是由念珠菌屬引起的，其治療方法隨著時間的推移而不斷發展。建議適當使用棘白菌素和廣譜唑類藥物治療黏膜念珠菌病、念珠菌血症和侵襲性念珠菌病等。易受真菌感染的人數不斷增加是市場的重要動力。此外，患者和醫療保健專業人員的意識不斷增強，預計將有助於增加抗真菌藥物的需求。

由於兒童皮膚感染盛行率不斷上升，預計皮癬菌病類別在整個預測期內將佔據重要的市場佔有率。在過去十年中，不健康的生活方式導致這種感染的盛行率顯著增加。免疫功能低下的患者尤其值得關注，因為他們容易受到真菌引起的嚴重病變和非典型症狀的影響。

其他適應症包括心內膜炎、鼻腦毛黴菌病和侵襲性肺部麴菌病。醫生面臨的主要挑戰之一是與細菌感染相比，侵襲性真菌感染的治療選擇有限。在過去 30 年中，僅開發了少數幾類治療分子。開發有效的治療藥物來管理免疫功能低下患者的全身真菌感染是產業參與者感興趣的關鍵領域。透過公私合作夥伴關係探索創新療法預計將為該行業帶來巨大的成長潛力。

區域洞察

北美市場在 2022 年佔據最大的收入佔有率，主要是由於美國和加拿大真菌感染和疾病的盛行率不斷上升。研發活動投資的增加、藥品批准數量的增加以及發達的醫療保健系統和治療設施進一步支持了該地區的收入成長。此外，市場受益於該地區主要參與者採取的策略性措施。例如，2021 年 4 月 28 日，輝瑞 (Pfizer Inc.) 宣布收購 Amplyx Pharmaceuticals, Inc.，這是一家私人公司，專注於開發治療免疫系統衰弱個體衰弱和危及生命疾病的藥物。 Amplyx 的主要化學物質 Fosmanogepix (APX001) 是一種正在開發的獨特實驗資產，用於治療侵襲性真菌感染。

在歐洲，由於研發項目的增加、醫療保健支出和基礎設施的增加以及 FDA 快速批准的推動，預計市場在預測期內將出現顯著的收入成長。值得注意的是，2021年12月15日，SCYNEXIS開發的一種用於治療和預防無法治癒和抗藥性感染的新型抗真菌藥物Ibrexafungerp獲得了歐洲藥品管理局（EMA）的孤兒藥資格認定，用於治療侵襲性念珠菌症。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球抗真菌藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（唑類、棘白菌素類、多烯類、烯丙胺類、其他）
    • 依適應症（念珠菌症、麴菌病、毛黴菌病、皮癬菌症、其他）
    • 依感染類型（表淺真菌感染、全身性真菌感染）
    • 依給藥途徑（局部、口服、腸胃外、其他）
    • 按最終使用者（家庭護理、醫院、診所、其他）
    • 依配銷通路（零售藥局、醫院藥局、網路藥局）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美抗黴菌藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按指示
    • 按感染類型
    • 依給藥途徑
    • 按最終用戶
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲抗黴菌藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按指示
    • 按感染類型
    • 依給藥途徑
    • 按最終用戶
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區抗黴菌藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按指示
    • 按感染類型
    • 依給藥途徑
    • 按最終用戶
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲抗黴菌藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按指示
    • 按感染類型
    • 依給藥途徑
    • 按最終用戶
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章 ：中東和非洲抗真菌藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按指示
    • 按感染類型
    • 依給藥途徑
    • 按最終用戶
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非抗真菌藥物
    • 沙烏地阿拉伯抗真菌藥物
    • 阿拉伯聯合大公國抗真菌藥物

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球抗真菌藥物市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 服務內容
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Abbott Laboratories Inc.
    • Astellas Pharma Inc.
    • Bayer AG
    • GSK plc
    • Glenmark Pharmaceuticals Limited
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Mycovia Pharmaceuticals, Inc.
    • Apex Laboratories Pvt. Ltd.

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 7786

Global Anti-Fungal Drugs Market has valued at USD 13.89 Billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.59% through 2028. Antifungal medications are commonly prescribed to treat fungal infections. These medications can be administered orally, topically, or intravenously via an IV drip. Fungal infections such as yeast infections, ringworm, nail and skin diseases can be caused by fungi present in the soil, air, and skin. Inhaling fungal spores may also lead to respiratory issues. Therefore, individuals with weakened immune systems are more susceptible to fungal infections, necessitating the use of antifungal medication. Most of these medications require a doctor's prescription, although a few are available over the counter.

There are two main categories of antifungal drugs: local and systemic. Depending on the specific condition being treated, local antifungals are commonly applied topically or vaginally, while systemic antifungals are administered orally or intravenously. Examples of systemically administered medicines include itraconazole, fluconazole, ketoconazole, voriconazole, posaconazole, and isavuconazole. Antifungal medications can function in one of two ways: they can directly kill fungal cells or inhibit their growth and development. Moreover, antifungal medications work by targeting structures or functions that are essential in fungal cells but not in human cells, allowing them to combat fungal infections without harming human cells. The fungal cell membrane and cell wall are frequently targeted components, as they surround and protect the fungal cell. Compromising either of these structures can cause the fungal cell to burst open and die.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 13.89 Billion
Market Size 2028USD 18.16 Billion
CAGR 2023-20284.59%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Rising Prevalence of Fungal Infections

The increasing prevalence of fungal infections is a key driver for the revenue growth in the market. Research indicates that fungal pathogens are responsible for approximately 13 million infections and 1.5 million deaths worldwide each year. Antifungal medications are also administered orally. On March 30, 2023, GSK plc and SCYNEXIS, Inc. announced an exclusive license agreement for Brexafemme, a first-in-class antifungal approved by the U.S. Food and Drug Administration (FDA) for the treatment of Vulvovaginal Candidiasis (VVC) and the reduction of the incidence of recurrent VVC (RVVC). This exclusive licensing deal grants GSK the sole right to commercialize Brexafemme for VVC and RVVC while continuing the development of ibrexafungerp, which is currently in phase III clinical trials for the possible treatment of Invasive Candidiasis (IC), a potentially fatal fungal infection.

The prevalence of fungal infections has been on the rise in recent years, prompting concerns within the healthcare industry. Contributing factors to this alarming trend include increasing global temperatures, the prevalence of chronic illnesses, and compromised immune systems. Hospital-acquired fungal infections, or nosocomial infections, have become a significant concern, with approximately 1.7 million hospitalized patients contracting such infections in 2019, according to the Centers for Disease Control and Prevention (CDC).

In response, the global antifungal drugs market is experiencing significant growth, with market players developing advanced treatment methods such as azoles to effectively combat these infections.

Increasing Hospitalizations

The increasing number of hospitalizations is a crucial factor contributing to the growing incidence of fungal infections acquired within healthcare settings. This is particularly prevalent among individuals with chronic illnesses such as cancer and those undergoing hematopoietic stem cell transplantation, whose weakened immune systems necessitate frequent hospital visits and extended stays. As these patients often require intensive medical interventions and prolonged periods of hospitalization, they become more susceptible to opportunistic fungal pathogens that thrive in healthcare environments.

It is important to note that these risks are even more pronounced in low and middle-income economies with inadequate healthcare infrastructure. In these settings, limited resources and overcrowding can further exacerbate the spread of nosocomial infections, posing a significant threat to patients' well-being. The lack of proper infection control measures and the absence of effective antifungal treatment options in these regions further compound the challenges faced by healthcare providers.

In light of these challenging conditions, the global antifungal drugs market is expected to flourish as it strives to address and combat these complex healthcare challenges. The development of innovative antifungal therapies and the implementation of comprehensive infection control protocols are paramount to reducing the burden of fungal infections and improving patient outcomes worldwide.

Increasing Investment for Healthcare Infrastructure

Another significant factor influencing the growth rate of the antifungal drugs market is the rising healthcare expenditure, which not only helps in improving infrastructure but also contributes to the development of advanced treatment options. With increased funding, healthcare facilities can upgrade their capabilities and invest in research and development to discover more effective antifungal medications.

Furthermore, there are rising initiatives by both public and private organizations to spread awareness about the prevalence and severity of myriad fungal infections. These awareness programs aim to educate the general public as well as healthcare professionals about the importance of early diagnosis and appropriate treatment. This concerted effort to enhance knowledge and understanding of fungal infections is expected to drive the demand for antifungal drugs and expand the market.

Additionally, the market is expected to witness growth due to factors such as high disposable income and the increasing availability of antifungal drugs as over-the-counter (OTC) medications. The ease of access and convenience offered by OTC antifungal drugs is likely to contribute to their widespread use and drive market expansion.

Moreover, the geriatric population is on the rise globally, leading to an increased prevalence of various medical conditions, including fungal infections. As a result, there is a growing demand for antifungal drugs in developing regions to cater to the healthcare needs of the aging population. This demographic shift, coupled with the rising consumption of antifungal drugs for various medical conditions, is expected to further enhance the growth rate of the antifungal drugs market. The combination of rising healthcare expenditure, awareness initiatives, availability of OTC drugs, and the increasing demand from the geriatric population is fueling the growth of the antifungal drugs market.

Increasing Number of Antifungal Drugs as Over the counter (OTC)

The increasing availability of antifungal drugs as over the counter (OTC) medications is indeed contributing to the rising demand for these pharmaceuticals. Antifungal drugs are essential for treating a wide range of fungal infections, including athlete's foot, yeast infections, and ringworm. OTC antifungal drugs are readily available at pharmacies, drugstores, and even online marketplaces. Patients can purchase them without needing a prescription, making them more accessible to individuals seeking relief from common fungal infections. The OTC availability empowers individuals to self-diagnose and self-treat common fungal infections. They no longer need to visit a healthcare professional for every minor infection, which not only saves time but also reduces the burden on healthcare systems. As OTC antifungal medications become more prevalent, consumers become increasingly aware of their availability and efficacy. This awareness drives the demand, as individuals are more likely to seek treatment when they know effective remedies are easily accessible. OTC antifungal drugs offer privacy and convenience to consumers. Many people prefer to address fungal infections discreetly without discussing their condition with a healthcare provider. This preference for privacy encourages individuals to purchase these medications independently.

The increasing number of antifungal drugs available as OTC medications is expanding their demand. This shift empowers consumers to take charge of their health and treat common fungal infections independently, contributing to the overall accessibility and utility of antifungal drugs in managing a range of fungal-related conditions.

Key Market Challenges

Adverse Health Effects

There are several disadvantages associated with antifungal drugs. One key factor is that individuals with weakened immune systems, such as those with acquired immunodeficiency syndrome (AIDS), lupus, cancer, and other conditions, are more susceptible to dangerous fungal infections known as opportunistic infections. This vulnerability poses a challenge to the revenue growth of the antifungal drug market.

Furthermore, the type of medicine, dosage strength, and the specific fungus being treated can all influence the outcome of the medication. Common side effects may include pain in the abdomen, unsettled stomach, diarrhea, and itchy, scorching, or rashy skin. These symptoms can also have a negative impact on the revenue growth of the market.

In addition to these challenges, antifungal medication can produce major side effects, including liver damage such as jaundice, anaphylaxis, and other severe allergic responses. Blisters and peeling skin are also symptoms of severe allergic skin reactions that can occur as a result of using antifungal drugs. Considering these factors, it becomes evident that while antifungal drugs are necessary for treating fungal infections, they do come with significant drawbacks that need to be taken into account.

Increasing Resistance to Antifungal Drugs

The increasing resistance to antifungal drugs is a concerning trend that has the potential to decrease the demand for these medications. Antifungal resistance occurs when fungi develop mechanisms to withstand the effects of antifungal drugs, rendering them less effective or ineffective. Antifungal resistance can complicate the treatment of fungal infections. When antifungal drugs become less effective, patients may require higher doses, prolonged treatment courses, or more potent medications. This can lead to increased healthcare costs and potential side effects, making individuals less inclined to seek treatment. As resistance emerges, it may limit the number of effective antifungal drugs available. This reduction in treatment options can be particularly problematic in cases of severe or drug-resistant fungal infections, potentially reducing the demand for antifungal drugs. The need for alternative antifungal drugs or combination therapies to combat resistant infections can lead to higher healthcare expenditures. Patients and healthcare providers may be hesitant to invest in expensive treatments, affecting the overall demand for these medications. Antifungal resistance is a public health concern as it can lead to treatment failures, increased mortality rates, and the spread of resistant fungal strains. Such concerns may prompt healthcare systems and organizations to implement stricter control measures, including the restriction of antifungal drug use, which can impact demand.

Key Market Trends

Increase In the Number of Research and Development Activities

The increase in the number of research and development (R&D) activities in the field of antifungal drugs is expected to significantly boost the demand for these medications. Antifungal drugs are critical for treating a wide range of fungal infections, from superficial conditions like athlete's foot to life-threatening systemic infections. Increasing R&D investments lead to the discovery of new antifungal compounds and formulations. These innovations are likely to result in the development of more effective drugs with improved mechanisms of action, enhancing the arsenal of treatment options available. R&D efforts are dedicated to understanding and combating antifungal resistance. Researchers are working to identify the mechanisms behind resistance and develop strategies to overcome it. This will ensure the continued effectiveness of antifungal drugs, driving their demand. Research in the field of fungal biology is uncovering specific molecular targets within fungal cells that can be exploited for drug development. Targeted therapies can enhance drug efficacy and reduce side effects, making antifungal drugs more appealing to healthcare providers and patients.

Technological Progress in Diagnostic Tests and Devices

Technological progress in diagnostic tests and devices is expected to play a crucial role in increasing the demand for antifungal drugs. Technological progress enables the earlier and more precise identification of fungal infections. Rapid diagnostic tests can quickly confirm the presence of fungi, allowing healthcare providers to initiate treatment promptly. This early intervention is critical for preventing the progression of fungal infections, increasing the demand for antifungal drugs. Advanced diagnostic methods can differentiate between various fungal species, helping tailor treatment approaches. Some antifungal drugs are more effective against specific fungi, and accurate species identification ensures the selection of the most appropriate medication, potentially driving the demand for targeted antifungal agents.

Modern diagnostic devices can assess the susceptibility of fungal isolates to different antifungal drugs. This information guides clinicians in choosing the most effective treatment, reducing the likelihood of resistance development and fostering demand for specific antifungal medications.

Segmental Insights

Drug Class Insights

In 2022, the Azoles medicine class segment, which includes popular therapeutics such as Noxafil, Diflucan, Vfend, and Cresemba, emerged as the leading market segment for antifungal drugs. This dominance can be attributed to the broad spectrum of activity exhibited by Azoles. By inhibiting fungal enzymes, these substances facilitate fungistatic actions. Azoles are prescribed for the treatment of ocular fungal infections, systemic candidiasis, blastomycosis, and candidemia. Triazoles and imidazoles, two types of azoles, are also utilized for managing systemic fungal infections due to their extensive range of activity and favorable safety profile. Triazoles possess superior absorption and distribution characteristics, fewer side effects, and minimal risk of drug interactions.

The market for antifungal medications is expected to witness slow growth, primarily due to the escalating drug resistance among Candida and Aspergillus species, particularly against azoles. Conversely, synthetic fungicidal compounds called allylamines are projected to exhibit a steady compound annual growth rate (CAGR) throughout the forecast period. These medications are recommended for the treatment of ringworm, athlete's foot, jock itch, and nail infections. Following fluconazole, Lamisil is the topical antifungal drug most frequently recommended by dermatologists for systemic antifungal therapy. Consequently, the increasing prevalence of dermatological conditions is anticipated to further augment the growth of this segment.

Indication Insights

The most prevalent systemic fungal infection, candidiasis, is projected to have the highest compound annual growth rate (CAGR) during the forecast period. It is caused by the Candida genus and its treatment has evolved over time. Appropriate use of echinocandins and broad-spectrum azoles is recommended for the treatment of mucosal candidiasis, candidemia, and invasive candidiasis, among other changes. The increasing number of individuals susceptible to fungal infections is a significant driver for the market. Furthermore, the growing awareness among patients and healthcare professionals is expected to contribute to the demand for antifungal medications.

The dermatophytosis category is expected to hold a significant market share throughout the forecast period due to the rising prevalence of skin infections in children. Unhealthy lifestyles have contributed to a significant increase in the prevalence of this infection over the past decade. Immunocompromised patients are particularly concerned due to their susceptibility to severe lesions and atypical symptoms caused by fungi.

Other indications include endocarditis, rhino-cerebral mucormycosis, and invasive pulmonary aspergillosis. One of the main challenges faced by physicians is the limited treatment options available for invasive fungal infections compared to bacterial infections. Only a few therapeutic molecule classes have been developed in the past 30 years. Developing effective therapeutic drugs for managing systemic fungal infections in immunocompromised patients is a key area of interest for industry players. The exploration of innovative therapies through public-private partnerships is expected to offer significant growth potential for the industry.

Regional Insights

North American market accounted for the largest revenue share in 2022, primarily driven by the increasing prevalence of fungal infections and diseases in the United States and Canada. This region's revenue growth is further supported by rising investments in research and development activities, a higher number of drug approvals, and the presence of well-developed healthcare systems and treatment facilities. Additionally, the market benefits from the strategic initiatives undertaken by major players in the region. For instance, on April 28, 2021, Pfizer Inc. announced the acquisition of Amplyx Pharmaceuticals, Inc., a privately held company focused on developing medicines for debilitating and life-threatening diseases in individuals with weakened immune systems. Amplyx's main chemical, Fosmanogepix (APX001), is a unique experimental asset in development for the treatment of invasive fungal infections.

In Europe, the market is expected to witness significant revenue growth during the forecast period, driven by increasing research and development projects, rising healthcare spending and infrastructure, and the fast-track FDA approvals. Notably, on December 15, 2021, Ibrexafungerp, a novel antifungal agent developed by SCYNEXIS to treat and prevent incurable and drug-resistant infections, received orphan medical product designation from the European Medicines Agency (EMA) for the indication of invasive candidiasis.

Key Market Players

  • Abbott Laboratories Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • GSK plc
  • Glenmark Pharmaceuticals Limited
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Mycovia Pharmaceuticals, Inc.
  • Apex Laboratories Pvt. Ltd.

Report Scope:

In this report, the Global Anti-Fungal Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Fungal Drugs Market, By Drug Class:

  • Azoles
  • Echinocandins
  • Polyenes
  • Allylamines
  • Others

Anti-Fungal Drugs Market, By Indication:

  • Candidiasis
  • Aspergillosis
  • Mucormycosis
  • Dermatophytosis
  • Others

Anti-Fungal Drugs Market, By Infection Type:

  • Superficial Fungal Infection
  • Systemic Fungal Infection

Anti-Fungal Drugs Market, By Route of Administration:

  • Topical
  • Oral
  • Parenteral
  • Others

Anti-Fungal Drugs Market, By End User:

  • Homecare Hospitals
  • Clinics
  • Others

Anti-Fungal Drugs Market, By Distribution Channel:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

Anti-Fungal Drugs Market, By End User:

  • Topical
  • Oral
  • Parenteral
  • Others

Anti-Fungal Drugs Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Anti-Fungal Drugs Market.

Available Customizations:

  • Global Anti-Fungal Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Fungal Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others)
    • 5.2.2. By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others)
    • 5.2.3. By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection)
    • 5.2.4. By Route of Administration (Topical, Oral, Parenteral, Others)
    • 5.2.5. By End User (Homecare, Hospitals, Clinics, Others)
    • 5.2.6. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy)
    • 5.2.7. By Region
    • 5.2.8. By Company (2022)
  • 5.3. Market Map

6. North America Anti-Fungal Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Indication
    • 6.2.3. By Infection Type
    • 6.2.4. By Route Of Administration
    • 6.2.5. By End User
    • 6.2.6. By Distribution Channel
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Anti-Fungal Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Infection Type
        • 6.3.1.2.4. By Route Of Administration
        • 6.3.1.2.5. By End User
        • 6.3.1.2.6. By Distribution Channel
    • 6.3.2. Canada Anti-Fungal Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Infection Type
        • 6.3.2.2.4. By Route Of Administration
        • 6.3.2.2.5. By End User
        • 6.3.2.2.6. By Distribution Channel
    • 6.3.3. Mexico Anti-Fungal Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Infection Type
        • 6.3.3.2.4. By Route Of Administration
        • 6.3.3.2.5. By End User
        • 6.3.3.2.6. By Distribution Channel

7. Europe Anti-Fungal Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Indication
    • 7.2.3. By Infection Type
    • 7.2.4. By Route Of Administration
    • 7.2.5. By End User
    • 7.2.6. By Distribution Channel
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Anti-Fungal Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Infection Type
        • 7.3.1.2.4. By Route Of Administration
        • 7.3.1.2.5. By End User
        • 7.3.1.2.6. By Distribution Channel
    • 7.3.2. United Kingdom Anti-Fungal Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Infection Type
        • 7.3.2.2.4. By Route Of Administration
        • 7.3.2.2.5. By End User
        • 7.3.2.2.6. By Distribution Channel
    • 7.3.3. Italy Anti-Fungal Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Infection Type
        • 7.3.3.2.4. By Route Of Administration
        • 7.3.3.2.5. By End User
        • 7.3.3.2.6. By Distribution Channel
    • 7.3.4. France Anti-Fungal Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Infection Type
        • 7.3.4.2.4. By Route Of Administration
        • 7.3.4.2.5. By End User
        • 7.3.4.2.6. By Distribution Channel
    • 7.3.5. Spain Anti-Fungal Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Infection Type
        • 7.3.5.2.4. By Route Of Administration
        • 7.3.5.2.5. By End User
        • 7.3.5.2.6. By Distribution Channel

8. Asia-Pacific Anti-Fungal Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Indication
    • 8.2.3. By Infection Type
    • 8.2.4. By Route Of Administration
    • 8.2.5. By End User
    • 8.2.6. By Distribution Channel
    • 8.2.7. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Anti-Fungal Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Infection Type
        • 8.3.1.2.4. By Route Of Administration
        • 8.3.1.2.5. By End User
        • 8.3.1.2.6. By Distribution Channel
    • 8.3.2. India Anti-Fungal Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Infection Type
        • 8.3.2.2.4. By Route Of Administration
        • 8.3.2.2.5. By End User
        • 8.3.2.2.6. By Distribution Channel
    • 8.3.3. Japan Anti-Fungal Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Infection Type
        • 8.3.3.2.4. By Route Of Administration
        • 8.3.3.2.5. By End User
        • 8.3.3.2.6. By Distribution Channel
    • 8.3.4. South Korea Anti-Fungal Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Infection Type
        • 8.3.4.2.4. By Route Of Administration
        • 8.3.4.2.5. By End User
        • 8.3.4.2.6. By Distribution Channel
    • 8.3.5. Australia Anti-Fungal Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Infection Type
        • 8.3.5.2.4. By Route Of Administration
        • 8.3.5.2.5. By End User
        • 8.3.5.2.6. By Distribution Channel

9. South America Anti-Fungal Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Indication
    • 9.2.3. By Infection Type
    • 9.2.4. By Route Of Administration
    • 9.2.5. By End User
    • 9.2.6. By Distribution Channel
    • 9.2.7. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Anti-Fungal Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Infection Type
        • 9.3.1.2.4. By Route Of Administration
        • 9.3.1.2.5. By End User
        • 9.3.1.2.6. By Distribution Channel
    • 9.3.2. Argentina Anti-Fungal Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Infection Type
        • 9.3.2.2.4. By Route Of Administration
        • 9.3.2.2.5. By End User
        • 9.3.2.2.6. By Distribution Channel
    • 9.3.3. Colombia Anti-Fungal Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Infection Type
        • 9.3.3.2.4. By Route Of Administration
        • 9.3.3.2.5. By End User
        • 9.3.3.2.6. By Distribution Channel

10. Middle East and Africa Anti-Fungal Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Indication
    • 10.2.3. By Infection Type
    • 10.2.4. By Route Of Administration
    • 10.2.5. By End User
    • 10.2.6. By Distribution Channel
    • 10.2.7. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Anti-Fungal Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Infection Type
        • 10.3.1.2.4. By Route Of Administration
        • 10.3.1.2.5. By End User
        • 10.3.1.2.6. By Distribution Channel
    • 10.3.2. Saudi Arabia Anti-Fungal Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Infection Type
        • 10.3.2.2.4. By Route Of Administration
        • 10.3.2.2.5. By End User
        • 10.3.2.2.6. By Distribution Channel
    • 10.3.3. UAE Anti-Fungal Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Infection Type
        • 10.3.3.2.4. By Route Of Administration
        • 10.3.3.2.5. By End User
        • 10.3.3.2.6. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Anti-Fungal Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Abbott Laboratories Inc.
    • 15.5.2. Astellas Pharma Inc.
    • 15.5.3. Bayer AG
    • 15.5.4. GSK plc
    • 15.5.5. Glenmark Pharmaceuticals Limited
    • 15.5.6. Merck & Co. Inc.
    • 15.5.7. Novartis AG
    • 15.5.8. Pfizer Inc.
    • 15.5.9. Mycovia Pharmaceuticals, Inc.
    • 15.5.10. Apex Laboratories Pvt. Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer